Found: 66
Select item for more details and to access through your institution.
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 7, p. 1006, doi. 10.1177/13524585211010070
- By:
- Publication type:
- Article
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Lack of Serum Oligoclonal Antibody Responses to Chlamydophila pneumoniae in Multiple Sclerosis.
- Published in:
- European Neurology, 2005, v. 53, n. 2, p. 81, doi. 10.1159/000084933
- By:
- Publication type:
- Article
Vitamin D and multiple sclerosis hospital admissions in Scotland.
- Published in:
- QJM: An International Journal of Medicine, 2011, v. 104, n. 11, p. 1001, doi. 10.1093/qjmed/hcr101
- By:
- Publication type:
- Article
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
- Published in:
- Multiple Sclerosis Journal, 2013, v. 19, n. 14, p. 1896, doi. 10.1177/1352458513485982
- By:
- Publication type:
- Article
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.
- Published in:
- Multiple Sclerosis Journal, 2012, v. 18, n. 7, p. 932, doi. 10.1177/1352458511433302
- By:
- Publication type:
- Article
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
- Published in:
- Multiple Sclerosis Journal, 2011, v. 17, n. 11, p. 1333, doi. 10.1177/1352458511412654
- By:
- Publication type:
- Article
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
- Published in:
- Multiple Sclerosis Journal, 2011, v. 17, n. 5, p. 578, doi. 10.1177/1352458510391344
- By:
- Publication type:
- Article
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2019, v. 5, n. 4, p. 1, doi. 10.1177/2055217319893103
- By:
- Publication type:
- Article
Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH).
- Published in:
- Journal of Neurochemistry, 2003, v. 85, p. 25, doi. 10.1046/j.1471-4159.85.s2.18_8.x
- By:
- Publication type:
- Article
Apple Ripening Is Controlled by a NAC Transcription Factor.
- Published in:
- Frontiers in Genetics, 2021, v. 11, p. 1, doi. 10.3389/fgene.2021.671300
- By:
- Publication type:
- Article
EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative.
- Published in:
- Infectious Agents & Cancer, 2022, v. 17, n. 1, p. 1, doi. 10.1186/s13027-022-00469-5
- By:
- Publication type:
- Article
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.
- Published in:
- ISRN Neurology, 2012, p. 1, doi. 10.5402/2012/802649
- By:
- Publication type:
- Article
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
- Published in:
- Acta Neurologica Scandinavica, 2013, v. 128, n. 6, p. e33, doi. 10.1111/ane.12151
- By:
- Publication type:
- Article
Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.
- Published in:
- Acta Neurologica Scandinavica, 2013, v. 128, n. 5, p. 321, doi. 10.1111/ane.12119
- By:
- Publication type:
- Article
Seroprevalence of herpes simplex virus type 2 in multiple sclerosis.
- Published in:
- Acta Neurologica Scandinavica, 2006, v. 114, n. 6, p. 363, doi. 10.1111/j.1600-0404.2006.00677.x
- By:
- Publication type:
- Article
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases.
- Published in:
- Clinical & Experimental Immunology, 2020, v. 202, n. 2, p. 149, doi. 10.1111/cei.13495
- By:
- Publication type:
- Article
Book Reviews.
- Published in:
- 1996
- By:
- Publication type:
- Book Review
Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?
- Published in:
- Clinical & Experimental Immunology, 2012, v. 167, n. 1, p. 1, doi. 10.1111/j.1365-2249.2011.04446.x
- By:
- Publication type:
- Article
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
- Published in:
- 2010
- By:
- Publication type:
- Opinion
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.
- Published in:
- Brain: A Journal of Neurology, 2008, v. 131, n. 7, p. 1736, doi. 10.1093/brain/awn119
- By:
- Publication type:
- Article
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.
- Published in:
- Brain: A Journal of Neurology, 2003, v. 126, n. 10, p. 2191
- By:
- Publication type:
- Article
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
- Published in:
- Brain: A Journal of Neurology, 2002, v. 125, n. 7, p. 1462, doi. 10.1093/brain/awf165
- By:
- Publication type:
- Article
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis.
- Published in:
- Brain: A Journal of Neurology, 1997, v. 120, n. 1, p. 1, doi. 10.1093/brain/120.1.1
- By:
- Publication type:
- Article
Neutralising antibodies to interferon β in multiple sclerosis.
- Published in:
- Journal of Neurology, 2007, v. 254, n. 7, p. 827, doi. 10.1007/s00415-006-0486-3
- By:
- Publication type:
- Article
Book Reviews.
- Published in:
- 2003
- By:
- Publication type:
- Book Review
Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis.
- Published in:
- Journal of Neurology, 2001, v. 248, n. 6, p. 487, doi. 10.1007/s004150170158
- By:
- Publication type:
- Article
Kupfermangel als behandelbare Ursache von Gleichgewichtsstörungen.
- Published in:
- Praxis (16618157), 2010, v. 99, n. 19, p. 1153, doi. 10.1024/1661-8157/a000258
- By:
- Publication type:
- Article
HLA-DRB1*15, low infant sibling exposure, and multiple sclerosis gene-environment interaction.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis.
- Published in:
- 2000
- By:
- Publication type:
- commentary
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis.
- Published in:
- 1996
- By:
- Publication type:
- letter
Nitric oxide and headache: related, but how?
- Published in:
- 2003
- By:
- Publication type:
- Editorial
Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2010, v. 16, n. 9, p. 1066, doi. 10.1177/1352458510375100
- By:
- Publication type:
- Article
Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography.
- Published in:
- Multiple Sclerosis (13524585), 2009, v. 15, n. 7, p. 795, doi. 10.1177/1352458509104594
- By:
- Publication type:
- Article
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
- Published in:
- Multiple Sclerosis (13524585), 2009, v. 15, n. 2, p. 219
- By:
- Publication type:
- Article
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
- Published in:
- Multiple Sclerosis (13524585), 2008, v. 14, n. 2, p. 212, doi. 10.1177/1352458507082066
- By:
- Publication type:
- Article
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2008, v. 14, n. 1, p. 59, doi. 10.1177/1352458507082061
- By:
- Publication type:
- Article
Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis -- are we there yet?
- Published in:
- Multiple Sclerosis (13524585), 2007, v. 13, n. 9, p. 1083
- By:
- Publication type:
- Article
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers.
- Published in:
- Multiple Sclerosis (13524585), 2006, v. 12, n. 3, p. 325, doi. 10.1191/135248505ms1277oa
- By:
- Publication type:
- Article
Acute axonal damage predicts clinical outcome in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2005, v. 11, n. 5, p. 532, doi. 10.1191/1352458505ms1218oa
- By:
- Publication type:
- Article
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2005, v. 11, n. 4, p. 492, doi. 10.1191/1352458505ms1187sr
- By:
- Publication type:
- Article
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2004, v. 10, n. 6, p. 713, doi. 10.1191/1352458504ms1107xx
- By:
- Publication type:
- Article
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2004, v. 10, n. 3, p. 281, doi. 10.1191/1352458504ms1021sr
- By:
- Publication type:
- Article
Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease.
- Published in:
- Multiple Sclerosis (13524585), 1999, v. 5, n. 5, p. 335, doi. 10.1191/135245899678846320
- By:
- Publication type:
- Article
The potential role of nitric oxide in multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 212, doi. 10.1191/135245898678909312
- By:
- Publication type:
- Article
Are there any body fluid markers of brain atrophy in multiple sclerosis?
- Published in:
- Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 138, doi. 10.1191/135245898678909303
- By:
- Publication type:
- Article
Urinary markers of disease activity in multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 247, doi. 10.1191/135245898678909321
- By:
- Publication type:
- Article